BNET Industries
Market Cap:$37.8K
- Public
- US
Dow Jones Description
We are a pharmaceutical research and development company specializing in photodynamic therapy, or PDT, a treatment modality based on drugs that respond to light. When activated by light, these drugs induce a photochemical reaction in the presence of oxygen that can be used to locally destroy diseased cells and abnormal blood vessels. We have branded our novel version of PDT technology with the trademark PhotoPointâ. Our drugs and devices are in various stages of development and require regulatory approval prior to sales, marketing or clinical use. Our most advanced drug, PHOTREX (formerly known as PhotoPoint® SnET2), generic name rostaporfin, has completed two Phase III clinical trials for the treatment of wet age-related macular degeneration, or AMD. We submitted a New Drug Application, or an NDA, for PHOTREX, to the U.S. Food and Drug Administration, or the FDA, for its marketing approval on March 31, 2004, with a priority review designation.
President
David E MaiContact Information
336 Bollay Drive
Santa Barbara, California 93117
8056859880
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
miravant medical technologies - All News and Analysis
StockGuru Price and Volume Alerts for Tuesday May 30, 2006 - Miravant Files Form 15 with the SEC while mPhase Technologies and Bell Labs Extend Agreement to Jointly Develop Nano- and MEMS-Based Applications.
- 2006-05-30
M2 PRESSWIRE-30 May 2006-Stockguru.com: StockGuru Price and Volume Alerts for Tuesday May 30, 2006 - Miravant Files Form 15 with the SEC while mPhase Technologies and Bell Labs Extend Agreement to Jointly Develop Nano- and MEMS-Based ApplicationsC1994-2006 M2 COMMUNICATIONS LTD RDATE:30052006 ...
Talking Stock Alerts for Thursday, May 11 2006: AMHI, DHCC, DVLN, SALN, and MRVT.
- 2006-05-11
M2 PRESSWIRE-11 May 2006-TalkingStocks.com: Talking Stock Alerts for Thursday, May 11 2006: AMHI, DHCC, DVLN, SALN, and MRVTC1994-2006 M2 COMMUNICATIONS LTD RDATE:11052006 Dallas, Texas - Talking Stock Alerts for Thursday include American Healthchoice Inc (OTCBB: AMHI), Diamondhead Casino Corporation (OTCBB: ...
Miravant Closes $41.5 Million Financing With Pharmacia & Upjohn
- 1999-02-24
SANTA BARBARA, Calif.--BW HealthWire--Feb. 24, 1999--Miravant Medical Technologies (Nasdaq:MRVT) today announced the closing of an equity investment and credit agreement with Pharmacia & Upjohn, Inc. (NYSE:PNU). Pharmacia & Upjohn has purchased 1,136,533 shares of additional Miravant common stock for $19 million ($16.71 per share) and has extended to Miravant a...
Miravant CEO Responds to Stock Sale
- 1998-09-18
SANTA BARBARA, Calif.--BUSINESS WIRE--Sept. 18, 1998--The reported selling of 50,000 shares of Miravant Medical Technologies (Nasdaq: MRVT) common stock by its Chairman and Chief Executive Officer, Gary S. Kledzik, Ph.D., was an involuntary sale of stock, without prior notice. Dr. Kledzik stated, "This was an isolated incident...
Miravant CEO Responds to Stock Sale
- 1998-09-18
SANTA BARBARA, Calif.--BUSINESS WIRE--Sept. 18, 1998--The reported selling of 50,000 shares of Miravant Medical Technologies (Nasdaq: MRVT) common stock by its Chairman and Chief Executive Officer, Gary S. Kledzik, Ph.D., was an involuntary sale of stock, without prior notice. Dr. Kledzik stated, "This was an isolated incident...
PDT Inc. Changes Name to Miravant Medical Technologies; Nasdaq Ticker Symbol to Become MRVT on Sept. 16th
- 1997-09-15
SANTA BARBARA, Calif.--BW HealthWire--Sept. 15, 1997--PDT Inc. (Nasdaq:PDTI) Monday announced that its name is now Miravant Medical Technologies (Nasdaq:MRVT). All addresses and phone numbers remain unchanged except the Web site, which is www.miravant.com, and the Nasdaq ticker symbol, which becomes MRVT at market open on Sept. 16th....
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| David E Mai | President |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Robert J Sutcliffe | Chairman |
| Organization | Position | Status |
|---|---|---|
| Miravant Medical Technologies | President | Current |
| Miravant | Current | |
| Boston Scientific Corporation | Vice President | Former |
| Boston Scientific Corporation | Director of Strategic Marketing | Former |
| University of Hawaii | B.S. degree in Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Cheniere Energy Partners, L.P. | Board of Directors | Current |
| Miravant Medical Technologies | Chairman | Current |
| Neurome, Inc. | Member of Neurome's Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
